Covance
LabCorp Expands Companion Dx Agreement With BML
The agreement will initially focus on making available assays developed and validated by LabCorp's Covance business, with the first assays targeting oncology.
NanoString Partners With CROs to Expand Access to Cancer Research Panel
The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
Biocartis, Covance Sign Commercialization Agreement for Idylla
Idylla molecular testing instruments will be placed at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.
Mission Bio, LabCorp Collaborate on Clinical Trials, Companion Dx Development
LabCorp's Covance business plans to offer single-cell services on Mission Bio's platform to pharma and to explore its use in companion diagnostics.
LabCorp Q2 Revenues Rise 5 Percent, Fueled by Diagnostics Growth
Total revenues reached $2.54 billion during the quarter, while LabCorp Diagnostics' revenues rose more than 8 percent to $1.80 billion.